|
Volumn 88, Issue 24, 1996, Pages 1834-1839
|
Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer
a a a a a a a a a a a a a a a a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
TAMOXIFEN;
ADULT;
AGED;
ANALYTIC METHOD;
ARTICLE;
BREAST CANCER;
CANCER CHEMOTHERAPY;
CANCER RECURRENCE;
CANCER RESEARCH;
CANCER SURVIVAL;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
HUMAN;
MAJOR CLINICAL STUDY;
MALE;
ORAL DRUG ADMINISTRATION;
RANDOMIZED CONTROLLED TRIAL;
RECURRENCE RISK;
RELAPSE;
RISK BENEFIT ANALYSIS;
ADMINISTRATION, ORAL;
AGED;
ANTINEOPLASTIC AGENTS, HORMONAL;
BREAST NEOPLASMS;
CHEMOTHERAPY, ADJUVANT;
DISEASE-FREE SURVIVAL;
DRUG ADMINISTRATION SCHEDULE;
ESTROGEN ANTAGONISTS;
FEMALE;
HUMANS;
LIFE TABLES;
MIDDLE AGED;
RISK;
SURVIVAL ANALYSIS;
TAMOXIFEN;
TIME FACTORS;
TREATMENT OUTCOME;
|
EID: 8044243594
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/88.24.1834 Document Type: Article |
Times cited : (82)
|
References (0)
|